Catalyst Pharmaceutical Partners Reports Second Quarter 2008 Financi...( which isCatalyst's version of vigabatri...)

Date:8/15/2008

, which is Catalyst's version of vigabatrin. CPP-109 has been granted "Fast Track" status by the U.S. Food & Drug Administration (FDA) for the treatment of cocaine addiction. This indicates that the FDA has recognized that CPP-109 is intended for the treatment of a serious or life-threatening condition for which there is no effective treatment and which demonstrates the potential to address unmet medical needs. For more information about the Company, please visit http://www.catalystpharma.com.

This press release contains forward-looking statements. Forward-looking statements involve known and unknown risks and uncertainties which may cause the Company's actual results in future periods to differ materially from forecasted results. A number of factors, including the Company's ability to successfully complete those clinical trials required for it to file a new drug application for CPP-109, the Company's ability to complete such trials on a timely basis within the budgets established for such trials, the Company's ability to protect its intellectual property and those other factors described in the Company's Annual Report on Form 10-K for 2007 and the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2008 that the Company has filed with the U.S. Securities and Exchange Commission ("SEC"), could adversely affect the Company. Copies of the Company's filings with the SEC are available from the SEC, may be found on the Company's website or may be obtained upon request from the Company. The Company does not undertake any obligation to update the information contained herein, which speaks only as of this date.

CATALYST PHARMACEUTICAL PARTNERS, INC.

(a development stage company)

CONDENSED STATEMENTS OF OPERATIONS (unaudited)

For the Three Months For the Six Months

'/>"/>

SOURCE Catalyst Pharmaceutical Partners, Inc. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5
Related biology technology :

1. Controlling the size of nanoclusters: First step in making new catalysts
2. Catalyst Pharmaceutical Partners, Inc. Files Form S-3 Shelf Registration Statement
3. IDEXX Laboratories Announces First Customer Deliveries of Catalyst Dx(TM) Chemistry Analyzer and SNAPshot Dx(TM) Analyzer
4. UCT Specialties (Formerly Petrarch) Announces the Release of Their New Product Guides for Silanes, Silicones, Platinum Catalyst and Glass Coatings
5. Experiments reveal unexpected activity of fuel cell catalysts
6. Using catalysts to stamp nanopatterns without ink
7. Huifeng Bio-Pharmaceutical (HFGB) Reports over $5 Million in Gross Sales; Record Results for the First Half of 2008
8. Indevus Pharmaceuticals Announces Issuance of U.S. Patent for SANCTURA XR(TM)
9. Access Pharmaceuticals to Present at the Noble Financial Equity Conference
10. Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman
11. VIA Pharmaceuticals to Present at Fourth Annual Noble Financial Equity Conference